Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will US Supreme Court Come To Teva’s Rescue On ‘Skinny Label’ Battle?

Israeli Firm Petitions For Certiorari Review Of Labelling Carve-Outs Litigation With GSK

Executive Summary

Teva has made good on its stated intention to bring its long-running US legal battle with GSK over “skinny-label” generics to the Supreme Court. In a detailed certiorari petition, the firm sets out its arguments for why the matter warrants review.

You may also be interested in...



Teva Plans To Take Skinny-Label Defeat To Supreme Court

Following the decision by the US Court of Appeals for the Federal Circuit not to rehear “en banc” Teva’s litigation with GSK revolving around skinny-label generic carvedilol, the Israeli company has confirmed that it will seek Supreme Court review of the ruling.

Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling

Teva has once again been instructed to compensate GSK with $235m in damages after a split US Court of Appeals reversed a lower court finding that Teva had not willfully induced infringement of a method-of-use patent shielding the originator’s Coreg antihypertensive.

What Aspects Will Give Humira Biosimilars The Edge In 2023?

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel